Request Demo
Last update 09 May 2026
AL-8326
Last update 09 May 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms AL 8326 |
Target |
Action inhibitors, antagonists |
Mechanism Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), FGFRs antagonists(Fibroblast growth factor receptors antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China), Special Review Project (China) |
Login to view timeline
Related
12
Clinical Trials associated with AL-8326NCT07132957
A Phase I Study to Evaluate the Mass Balance of 14C-labeled AL8326 in Healthy Subjects
NCT06247605
Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment
NCT05363280
A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment
100 Clinical Results associated with AL-8326
Login to view more data
100 Translational Medicine associated with AL-8326
Login to view more data
100 Patents (Medical) associated with AL-8326
Login to view more data
100 Deals associated with AL-8326
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Small Cell Lung Cancer | Phase 3 | China | 26 Oct 2023 | |
| Non-Small Cell Lung Cancer | Phase 2 | United States | 01 Nov 2022 | |
| Non-Small Cell Lung Cancer | Phase 2 | Spain | 01 Nov 2022 | |
| Recurrent Lung Small Cell Carcinoma | Phase 2 | United States | 01 Nov 2022 | |
| Recurrent Lung Small Cell Carcinoma | Phase 2 | Spain | 01 Nov 2022 | |
| Renal Cell Carcinoma | Phase 2 | United States | 01 Nov 2022 | |
| Renal Cell Carcinoma | Phase 2 | Spain | 01 Nov 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 26 Oct 2021 | |
| Metastatic Solid Tumor | Phase 2 | China | 26 Oct 2021 | |
| Bile Duct Neoplasms | Phase 1 | China | 01 Jun 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Small Cell Lung Cancer Third line | 30 | msagcspyie(cjhtsoclck) = iczdvkngir nyvpmfyvga (bmgpdqebsg ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free